Changes in gene expression during progression of ovarian carcinoma

被引:128
作者
Tapper, J
Kettunen, E
El-Rifai, W
Seppälä, M
Andersson, LC
Knuutila, S
机构
[1] Univ Helsinki, Haartman Inst, Dept Med Genet, FIN-00029 Helsinki, Finland
[2] Univ Helsinki, Cent Hosp, FIN-00029 Helsinki, Finland
[3] Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, FIN-00029 Helsinki, Finland
[4] Univ Helsinki, Cent Hosp, Dept Pathol, FIN-00029 Helsinki, Finland
关键词
D O I
10.1016/S0165-4608(01)00386-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The molecular events leading to the development and progression of serous ovarian carcinoma are not completely understood. We performed a large scale survey for the identification of differentially expressed genes in serous ovarian carcinoma by using cDNA array analysis. Differences in gene expression between serous adenocarcinoma and benign serous adenoma, and between advanced and/or moderately or poorly differentiated and local, highly differentiated serous adenocarcinoma were assessed. The most striking difference between adenocarcinoma and benign adenoma was upregulation of RHOGDI2 in the carcinomas irrespective of the clinical tumor stage. Other changes in carcinoma were upregulation of MET and Ne-dlg, and downregulation of HG-FAC, desmin, and PDGFA. The most prominent differences between advanced and local adenocarcinoma were upregulation of COL3A1, CFGR, and MET in advanced carcinoma, and down-regulation of HGFAC, FZD3, and BFL1 in the same tumors. In conclusion, significant differences were found in the gene expression between benign and malignant serous ovarian tumors, and between local, highly differentiated and advanced and/or moderately or poorly differentiated serous adenocarcinomas. The differentially expressed genes may be related to the carcinogenesis and progression of the malignant growth. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 25 条
  • [1] [Anonymous], BLAUSTEINS PATHOLOGY
  • [2] MOLECULAR ALTERATIONS OF THE AKT2 ONCOGENE IN OVARIAN AND BREAST CARCINOMAS
    BELLACOSA, A
    DEFEO, D
    GODWIN, AK
    BELL, DW
    CHENG, JQ
    ALTOMARE, DA
    WAN, MH
    DUBEAU, L
    SCAMBIA, G
    MASCIULLO, V
    FERRANDINA, G
    PANICI, PB
    MANCUSO, S
    NERI, G
    TESTA, JR
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1995, 64 (04) : 280 - 285
  • [3] BERCHUCK A, 1990, CANCER RES, V50, P4087
  • [4] Hormone therapy failure in human prostate cancer:: Analysis by complementary DNA and issue microarrays
    Bubendorf, L
    Kolmer, M
    Kononen, J
    Koivisto, P
    Mousses, S
    Chen, YD
    Mahlamäki, E
    Schraml, P
    Moch, H
    Willi, N
    Elkahloun, AG
    Pretlow, TG
    Gasser, TC
    Mihatsch, MJ
    Sauter, G
    Kallioniemi, OP
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (20) : 1758 - 1764
  • [5] Danley DE, 1996, J IMMUNOL, V157, P500
  • [6] DeRisi J, 1996, NAT GENET, V14, P457
  • [7] Interferon-gamma regulates collagen and fibronectin gene expression by transcriptional and post-transcriptional mechanisms
    Diaz, A
    Jimenez, SA
    [J]. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 1997, 29 (01) : 251 - 260
  • [8] OVEREXPRESSION OF THE MET HGF RECEPTOR IN OVARIAN-CANCER
    DIRENZO, MF
    OLIVERO, M
    KATSAROS, D
    CREPALDI, T
    GAGLIA, P
    ZOLA, P
    SISMONDI, P
    COMOGLIO, PM
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1994, 58 (05) : 658 - 662
  • [9] Ghazizadeh M, 1997, AM J CLIN PATHOL, V107, P451
  • [10] IWABUCHI H, 1995, CANCER RES, V55, P6172